ADENOVIRUS DIAGNOSTIC TESTING MARKET ANALYSIS

Leading Companies

Adenovirus Diagnostic Testing Market – Competitive Landscape

Manufactures are offering various immunoassays for the detection of adenovirus antigen. SD BIOLINE Rota/Adeno Ag test, is one of the immune-chromatographic assays offered by Abbott, for the qualitative detection of the presence of rotavirus or adenovirus antigen in human fecal specimens. Furthermore, in 2017, Abbott collaborated with University of California, San Francisco (UCSF) to discover and characterize novel viruses as well as develop diagnostic tools to address the potential health threats cause by adenoviruses. Vendors also focusing on improving the quality of their assays by conducted surveillance projects at various hospitals, which in turn, is expected to create lucrative opportunities for growth in this market. For instance, BioMérieux SA conducted surveillance of rotavirus in hospitals and health centers in Niger from 2010 to 2012, using the RDT VIKIA Rota-Adeno assay to check their product accuracy. After receiving concerns regarding this test, company subsequently performed a parallel evaluation of the diagnostic accuracy of VIKIA Rota-Adeno RDT test assay, which is a good alternative for use in peripheral health centers where laboratory capacity is limited.

Player operating in the adenovirus diagnostic testing market include Affymetrix, Inc., Becton Dickinson and company, F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., Novartis AG, Qiagen N.V., DiaSorin Inc., Abbott Laboratories, and bioMerieux.